{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab"}],"populationDescription":"Safety Population. No participants were found positive for ADAs, hence participants were not analyzed for concentration of ADAs.","reportingStatus":"POSTED","timeFrame":"Up to 153 weeks","title":"DE Phase: Concentration of ADAs Against Dostarlimab When Administered in Combination With Belantamab Mafodotin","type":"SECONDARY"}